Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Karyopharm Therapeutics (KPTI) Shares Outstanding (Diluted Average) (2020 - 2025)

Karyopharm Therapeutics' Shares Outstanding (Diluted Average) history spans 6 years, with the latest figure at $8470.0 for Q1 2025.

  • For Q1 2025, Shares Outstanding (Diluted Average) rose 10.0% year-over-year to $8470.0; the TTM value through Mar 2025 reached $8470.0, up 10.0%, while the annual FY2023 figure was $114.2 million, 39.51% up from the prior year.
  • Shares Outstanding (Diluted Average) reached $8470.0 in Q1 2025 per KPTI's latest filing, down from $154.4 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $154.4 million in Q2 2024 to a low of $7700.0 in Q1 2024.
  • Average Shares Outstanding (Diluted Average) over 5 years is $82.4 million, with a median of $79.4 million recorded in 2022.
  • Peak YoY movement for Shares Outstanding (Diluted Average): surged 46.29% in 2023, then tumbled 99.99% in 2024.
  • A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $75.2 million in 2021, then rose by 8.84% to $81.9 million in 2022, then surged by 39.51% to $114.2 million in 2023, then surged by 35.2% to $154.4 million in 2024, then tumbled by 99.99% to $8470.0 in 2025.
  • Per Business Quant, the three most recent readings for KPTI's Shares Outstanding (Diluted Average) are $8470.0 (Q1 2025), $154.4 million (Q2 2024), and $7700.0 (Q1 2024).